Paola Tiberi

Paola Tiberi

Auto-generated profile, based on publicly available information

Paola Tiberi

Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
PTPatrizia Tornabene
Patrizia Tornabene
ITIvana Trapani
Ivana Trapani
RMRenato Minopoli
Renato Minopoli
MCMiriam Centrulo
Miriam Centrulo
MLMariangela Lupo
Mariangela Lupo
AAAlberto Auricchio
Alberto Auricchio
Adeno-associated viral vectors reconstitute large proteins in the retina via intein-mediated protein trans-splicing.

28 March 2025 in Science Advances
Verified
Journal Article
Open access
RFRita Ferla
Rita Ferla
EPEugenio Pugni
Eugenio Pugni
MLMariangela Lupo
Mariangela Lupo
PTPaola Tiberi
Paola Tiberi
FFFederica Fioretto
Federica Fioretto
ITIvana Trapani
Ivana Trapani
Retinal gene therapy using dual adeno-associated viral (AAV) intein vectors can be applied to genetic forms of blindness caused by mutations in genes with coding sequences that exceed single AAV cargo capacity, such as Stargardt disease (STGD1), the most common inherited macular dystrophy. In view of clinical translation of dual AAV intein vectors, here we set to evaluate both the efficiency and safety of their subretinal administration in relevant large animal models. Accordingly, we have developed the first pig model of STGD1, which we found to accumulate lipofuscin similarly to patients. This accumulation is significantly reduced upon subretinal administration of dual AAV intein vectors whose safety and pharmacodynamics we then tested in nonhuman primates, which showed modest and reversible inflammation as well as high levels of photoreceptor transduction. This bodes well for further clinical translation of dual AAV intein vectors in patients with STGD1 as well as for other blinding diseases that require the delivery of large genes.

11 November 2022 in Drug Safety
Verified
Journal Article
Open access
PDF file
PSPuneet Vir Singh
Puneet Vir Singh
PTPaola Tiberi
Paola Tiberi
GDGabriele Filippo Di Domenico
Gabriele Filippo Di Domenico
VRValerio Romolini
Valerio Romolini
TMThembile Mzolo
Thembile Mzolo
MPMichele Pellegrini
Michele Pellegrini
Introduction The currently licensed quadrivalent MenACWY-CRM conjugate vaccine presentation consists of two vials (lyophilized MenA and liquid MenCWY) to be reconstituted before injection. A new fully liquid, single-vial formulation has been developed to simplify administration and prevent reconstitution errors. We present pooled safety data from two randomized, controlled, observer-blind phase 2b clinical trials, in which the fully liquid presentation was compared with the licensed presentation. Methods This is a post hoc analysis of two studies, in which safety data from participants aged 10–40 years who received one dose of either liquid MenACWY-CRM (1337 participants; MenACWY liquid group) or licensed MenACWY-CRM (1332 participants; MenACWY licensed group) were pooled. Frequencies were calculated for solicited adverse events (AEs) during 7 days post-vaccination and unsolicited AEs, including medically attended AEs and serious AEs (SAEs), during the 6-month safety follow-up period. Analysis results are presented by vaccine group, overall and by age category (10–17 and 18–40 years). Results Overall, AEs solicited for collection during the first 7 days after vaccination were reported by similar percentages of participants (69.2%, MenACWY liquid; 68.2%, MenACWY licensed), and were generally mild/moderate in intensity. Solicited local AEs were reported by 46.0% of the MenACWY liquid group and 43.5% of the MenACWY licensed group and solicited systemic AEs by 55.2 and 54.1%, respectively. During the 6-month post-vaccination period, unsolicited AEs were reported by 32.2 and 31.2% of the MenACWY liquid group and MenACWY licensed group, respectively, and medically attended AEs by 18.6 and 17.3%, respectively. Overall, 14 participants in each group (1.0 and 1.1%, respectively) reported SAEs, none of which was considered vaccine-related by the investigator. The safety profiles of both MenACWY-CRM presentations were similar for each age group and overall. Conclusions This pooled analysis shows the safety profile of fully liquid MenACWY-CRM is comparable with that of the currently licensed vaccine presentation. Clinical Trial Registration ClinicalTrials.gov Identifiers: NCT03652610 (August 29, 2018), NCT03433482 (14 February 2018). Graphical abstract